Losartan for the nephropathy of sickle cell anemia: A phase ‐2, multicenter trial

This study forms the basis for a phase‐3, randomized, placebo‐controlled trial of losartan for the nephropathy of SCA.

Source: American Journal of Hematology - July 19, 2017 Category: Hematology Authors: Charles T. Quinn, Santosh L. Saraf, Victor R. Gordeuk, Courtney D. Fitzhugh, Susan E. Creary, Prasad Bodas, Alex George, Ashok B. Raj, Alecia C. Nero, Catherine E. Terrell, Lisa McCord, Adam Lane, Hans C. Ackerman, Yu Yang, Omar Niss, Michael D. Taylor, P Tags: RESEARCH ARTICLE Source Type: research